High-activity and high-thermal-stability heparin N-sulfated transferase mutant as well as coding gene and application thereof
By mutation of N-sulfate transferase at 24 amino acid sites, a high-activity and high-thermal stability mutant M8 was designed, which solved the problem of reduced activity of wild-type enzymes at high temperatures and achieved high-efficiency chemical enzymes of heparin The method has synthesized and expanded the scope of application.
Patent Information
- Application Number
- CN202310558380.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-18
AI Technical Summary
Wild-type N-sulfate transferase exhibits low activity and stability when expressed in the prokaryotic system, limiting the chemical enzymatic synthesis efficiency and product quality of heparin, and it is difficult to maintain activity at high temperatures.
A N-sulfate transferase mutant M8 was designed. Through mutations at 24 amino acid sites, the enzyme activity and high temperature stability were improved, and the construction of recombinant vectors and host cells was achieved in E. coli OrigamiB ( DE3) Highly efficient expression and purification.
The mutant M8 still maintains about 50% activity at 37°C for 7 days, significantly improving the chemical enzymatic synthesis efficiency of heparin, expanding the scope of application, making it possible to synthesize heparin at high temperatures, and promoting the application of heparin bionic synthesis. Technological development.
Smart Images

Figure BDA0004234168860000051 
Figure BDA0004234168860000052 
Figure HDA0004234168870000011
Abstract
Description
Technical Field
[0001] The invention relates to a highly active and highly thermally stable heparin N-sulfatase mutant and a coding gene and application thereof, belonging to the field of biotechnology. Background Art
[0002] Heparin (HP) is an important glycosaminoglycan, which is composed of repeating disaccharide units of D-β-glucuronic acid (or L-α-iduronic acid) and N-acetylglucosamine. Heparin has great medicinal value. In addition to its various applications as an anticoagulant, it can also be used to treat angina pectoris, nephrotic syndrome, severe burns, rheumatoid arthritis, etc. Its demand is always at the forefront of the field of biotechnology drugs in the world.
[0003] Heparin is mainly produced by extracting from animal tissues and organs such as bovine lungs and pig intestinal mucosa. However, the natural extraction method has low safety, low yield, high solvent consumption, serious environmental pollution, and the product quality is difficult to control due to the large differences in raw materials. It is easy to introduce impurities (such as chondroitin sulfate) during the production process. The large-scale heparin contamination incident that broke out in 2008 caused the death of nearly 100 patients. The occurrence of this incident greatly promoted the development of non-animal source heparin production. The chemical enzymatic synthesis strategy has strong stereoselectivity, high yield, mild reaction, uniform and stable product quality, and easy derivatization and modification of functional groups. It is of great significance for the development of new drugs and is expected to develop into an ideal new technology for the synthesis of heparin oligosaccharides. The tool enzyme used in the chemical enzymatic method is a restrictive step in promoting the further development of this strategy.
[0004] In the in vivo heparin synthesis pathway, N-deacetyl / N-sulfotransferase (NDST) is a bifunctional enzyme with two enzyme domains, one is the N-deacetyl active domain of N-deacetylase; the other is the N-sulfotransferase domain (N-Sulfotransferase, NST). Among them, the N-sulfotransferase domain can convert GlcNAc residues into N-sulfated glucosamine (GlcNS) residues. The N-deacetylase domain removes the acetyl group from GlcNAc to form N-unsubstituted glucosamine (GlcNH2). The NDST modification step is crucial for the biosynthesis of HS, because other HS biosynthetic enzymes, such as C5-epimerase, 2-O-sulfotransferase and 3-O-sulfotransferase, require the presence of GlcNS residues to complete their modification.
[0005] Since the degree of N-sulfation determines the pharmacological activity of heparin to a large extent, the activity of N-sulfotransferase is crucial in the enzymatic synthesis in vitro. However, wild-type N-sulfotransferases show low activity and stability in prokaryotic expression due to the lack of protein glycosylation. So far, there have been no reports on systematic protein engineering based on N-sulfotransferases. Summary of the invention
[0006] In view of the problems existing in the prior art, the present invention provides a highly active and highly thermally stable heparin N-sulfatase mutant and its encoding gene and application.
[0007] The technical solution of the present invention is as follows:
[0008] In a first aspect of the present invention, there is provided an N-sulfotransferase mutant M8, the amino acid sequence of which is shown in SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.1;
[0009] The N-sulfatase mutant M8 is a wild-type N-sulfatase in which 24 amino acids are mutated; the mutations are specifically: G625S, S637P, E660D, R688K, V699I, D721N, S738D, S742K, K743E, I761L, N771S, K779Q, E784D, T801I, T807H, L842E, D843E, S741P, A767Y, E839P, A846K, T869P, Y864H, and T872L.
[0010] Compared with the wild-type N-sulfotransferase, the N-sulfotransferase mutant M8 has glycine at position 625 mutated to serine, serine at position 637 mutated to proline, glutamic acid at position 660 mutated to aspartic acid, arginine at position 688 mutated to lysine, valine at position 699 mutated to isoleucine, aspartic acid at position 721 mutated to asparagine, serine at position 738 mutated to aspartic acid, serine at position 742 mutated to lysine, lysine at position 743 mutated to glutamic acid, isoleucine at position 761 mutated to leucine, and asparagine at position 771 mutated to serine. , lysine at position 779 mutated to glutamine, glutamate at position 784 mutated to aspartic acid, threonine at position 801 mutated to isoleucine, threonine at position 807 mutated to histidine, leucine at position 842 mutated to glutamate, aspartic acid at position 843 mutated to glutamate, serine at position 741 mutated to proline, alanine at position 767 mutated to tyrosine, glutamate at position 839 mutated to proline, alanine at position 846 mutated to lysine, threonine at position 869 mutated to proline, tyrosine at position 864 mutated to histidine, and threonine at position 872 mutated to leucine.
[0011] Preferably according to the present invention, the wild-type N-sulfatase is the N-Sulfotransferase domain (L557-R882) of the wild-type human N-deacetyl / N-sulfatase NDST-1, and the N-Sulfotransferase domain contains 325 amino acids; the NCBI accession number of the wild-type human N-deacetyl / N-sulfatase NDST-1 is P52848.1.
[0012] The second aspect of the present invention provides an expression cassette or a recombinant vector containing the coding gene of the N-sulfotransferase mutant M8. The recombinant vector has no particular restrictions on the starting vector and can be any vector known in the art as long as it can be replicated in the host. For example, the vector includes but is not limited to plasmids and bacteriophages. Once transformed into a suitable host, the vector can replicate and function independently of the host genome, or in some cases integrate into the genome itself.
[0013] Preferably according to the present invention, the recombinant vector is obtained by connecting the coding gene of the N-sulfatase mutant M8 with an expression vector, and the expression vector is a plasmid.
[0014] Further preferably, the plasmid is pGEX-4T-1.
[0015] The third aspect of the present invention provides a recombinant host cell containing the coding gene of the N-sulfotransferase mutant M8. The "host cell" has the meaning generally understood in the art, and is a host cell into which the coding gene of the mutant of the present invention can be introduced, and is called a recombinant host cell after the introduction. The strain of the present invention can be a prokaryotic cell or a eukaryotic cell, preferably a prokaryotic cell, and more preferably an Escherichia coli OrigamiB (DE3).
[0016] The fourth aspect of the present invention provides a method for producing N-sulfatase mutant M8 by fermentation, the method comprising culturing the above-mentioned host cell and isolating and obtaining the N-sulfatase mutant.
[0017] Preferably, according to the present invention, the specific steps of the method for producing N-sulfatase mutant M8 by fermentation are: culturing the recombinant host cells containing the coding gene of the N-sulfatase mutant M8 in LB liquid culture medium to an OD600 of 0.6 to 0.8, adding IPTG to induce expression for 16 to 18 hours; collecting the cells, ultrasonically disrupting, centrifuging and filtering, and purifying through the GST tag to obtain the N-sulfatase mutant M8.
[0018] The fifth aspect of the present invention provides the use of the above-mentioned N-sulfatase mutant M8 in the synthesis of N-site sulfated heparin oligosaccharides and polysaccharides.
[0019] Preferably, according to the present invention, the application is to use 3'-phosphoadenosine-5'phosphosulfate (PAPS) as a donor and heparin oligosaccharides and polysaccharides with a -GlcNH2-GlcA- structure as starting acceptors to catalyze the reaction to generate N-sulfated oligosaccharides and polysaccharides with a structure of -GlcNS-GlcA-.
[0020] Experimental operations not described in detail in the present invention can be performed according to conventional experimental operations in the technical field.
[0021] Beneficial Effects
[0022] 1. The N-sulfotransferase mutant M8 provided by the present invention is a new artificial heparin N-sulfotransferase, which has 24 amino acid mutations compared to the wild-type N-sulfotransferase (the L557-R882 part of NCBI accession number P52848.1), and has the activity of transferring sulfate to -GlcNH2-GlcA- of the heparin structure. According to the stability test, compared with the wild-type N-sulfotransferase which loses all activity after only less than one day of incubation at 37°C, the N-sulfotransferase mutant M8 of the present invention has high activity and extremely strong high thermal stability, and can maintain about 50% of its activity after incubation at 37°C for 7 days.
[0023] 2. The N-sulfatase mutant M8 provided by the present invention effectively improves the efficiency of the chemoenzymatic synthesis of heparin, expands the application range of N-sulfatase, makes it possible to synthesize heparin at high temperature, greatly promotes the development of bionic synthesis of heparin, and opens a new chapter for the research and development of glycosaminoglycans. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 RMSF analysis of each amino acid of wild-type N-sulfotransferase and simulated glycosylated N-sulfotransferase obtained from 20 ns molecular dynamics simulation at 37°C.
[0025] In the figure: the horizontal axis is the amino acid site, and the vertical axis is ΔRMSF.
[0026] Figure 2 This is an amino acid conservation analysis obtained by aligning more than a thousand homologous sequences of wild-type N-sulfotransferases.
[0027] In the figure: the horizontal axis is the amino acid site, and the vertical axis is the conservation score of the amino acid residues.
[0028] Figure 3 Comparison of the residual enzyme activity and expression levels of four N-sulfotransferase mutants after incubation at 37°C for 24 hours calculated by PROSS.
[0029] In the figure: the horizontal axis represents the N-sulfatase mutant, and the vertical axis represents the enzyme activity.
[0030] Figure 4 Prediction results for virtual saturation screening.
[0031] Figure 5 Activity assay results of the N-sulfatase mutant M8 point mutation
[0032] In the figure: the horizontal axis represents different enzymes or mutants, and the vertical axis represents the residual enzyme activity after being kept at 50°C for 0.5h, in order to evaluate its stability.
[0033] Figure 6 Activity assay results of iterative mutants of N-sulfotransferase mutant M8
[0034] In the figure: the horizontal axis represents different enzymes or mutants, and the vertical axis represents the residual enzyme activity after being kept at 50°C for 0.5h, in order to evaluate its stability.
[0035] Figure 7 Comparison of the activities and stabilities of wild-type N-sulfotransferase, N-sulfotransferase mutant M1 and N-sulfotransferase mutant M8.
[0036] In the figure: the horizontal axis represents different enzymes or mutants, and the vertical axis represents the enzyme activity and stability.
[0037] Figure 8 The residual enzyme activities of wild-type N-sulfotransferase and N-sulfotransferase mutant M8 after incubation at 37°C for different time periods.
[0038] In the figure: the horizontal axis is the time of keeping at 37°C, and the vertical axis is the conversion rate of the substrate. DETAILED DESCRIPTION
[0039] The technical solution of the present invention is further described below in conjunction with the embodiments and the accompanying drawings, but the protection scope of the present invention is not limited thereto. Unless otherwise specified, the technical means used in the present invention are methods well known to those skilled in the art.
[0040] The expression and purification methods of the N-sulfatase mutant recombinant proteins involved in the following examples are as follows:
[0041] After the amino acid sequences of the N-sulfotransferase mutants were optimized for Escherichia coli codons, Nanjing GenScript Co., Ltd. was commissioned to synthesize or mutate, and cloned into the pGEX-4T-1 vector, respectively. Then, they were chemically transformed into OrigamiB (DE3) competent cells and cultured on LB solid medium containing carbenicillin (50 μg / mL) for 12 h. Transformants were screened (negative control experiments were performed at the same time) to obtain positive transformants.
[0042] Pick a single colony of the N-sulfotransferase mutant positive transformant into a 20mL sterilized LB liquid medium (containing 50μg / ml carbenicillin) for activation culture (37°C, 225r / min). The overnight activated culture was inoculated into 1L LB liquid medium (containing 50μg / ml carbenicillin) at a 1% inoculum for expansion culture, and cultured at 37°C, 225r / min for 4 hours until OD600 was about 0.8, and IPTG was added at a final concentration of 0.2mM, and induced expression for 16-18h at 22°C, 225r / min. The bacteria were collected by centrifugation, resuspended with 1×PBS buffer, and ultrasonically broken on ice (working 3s, resting 5s, amplitude 33%, energy 1500KJ, 4°C) for 30min, and the broken bacteria were centrifuged at 12000rpm for 20min (4°C), and the supernatant was filtered with a 0.22um filter membrane. Use GST chromatography column for purification, wash with 1×PBS buffer after loading, and finally elute with 1×PBS buffer containing 10mM reduced glutathione to obtain the target protein. The purified protein is stored in 20% glycerol and stored in a -80℃ refrigerator. The wild-type N-sulfotransferase is expressed and purified in the same way. The purified N-sulfotransferase mutant protein is identified by polyacrylamide gel electrophoresis (SDS-PAGE). The protein concentration of NST and mutants is determined using the BCA protein concentration assay kit (Biyuntian P0011).
[0043] Wild-type N-sulfotransferase was expressed and purified in the same manner.
[0044] The methods for determining the activity and stability of the N-sulfatase mutant recombinant protein involved in the following examples are as follows:
[0045] 1. Determination of the sulfation activity of N-sulfatase mutants
[0046] The deacetylheparin pentasaccharide GlcA-GlcNH2-GlcA-GlcNH2-GlcA-pNP was used as the acceptor substrate and PAPS was used as the donor substrate for the reaction. The reaction system is shown in Table 1. The reaction was placed in a water bath at 37°C for 0.5h, and the enzyme was inactivated by heating with boiling water for 5min to terminate the reaction. The reaction solution was filtered with a 0.22μm filter membrane and then HPLC was performed according to the method described in Table 2. The pNP group of the monosaccharide acceptor has specific absorption at the ultraviolet detection wavelength of 310nm, and the flow rate of the mobile phase is 0.5ml / min. The activity of transferring 1μmol sulfate to the acceptor substrate per hour is defined as 1IU, and the unit is μmol / h.
[0047] Table 1. Reaction system for determination of sulfate transfer activity of N-sulfatase mutants
[0048]
[0049] Table 2. HPLC analysis method used for detection of heparin oligosaccharides
[0050]
[0051] 2. Stability determination of sulfatase activity of N-sulfatase mutants
[0052] The deacetyl heparin pentasaccharide GlcA-GlcNH2-GlcA-GlcNH2-GlcA-pNP was used as the acceptor substrate and PAPS was used as the donor substrate. The reaction system is shown in Table 1. First, the enzyme was kept at 50°C for 0.5h, and then the substrate was added. The reaction was then placed in a water bath at 37°C for 0.5h. The enzyme was inactivated by heating with boiling water for 5min to terminate the reaction. The reaction solution was filtered with a 0.22μm filter membrane and then HPLC was performed according to the method described in Table 2. The pNP group of the monosaccharide acceptor has specific absorption at the ultraviolet detection wavelength of 310nm, and the mobile phase flow rate is 0.5ml / min. The activity of transferring 1μmol sulfate to the acceptor substrate per hour is defined as 1IU, and the unit is μmol / h.
[0053] The activity and stability of the wild-type N-sulfotransferase were determined in the same manner.
[0054] Example 1: PROSS algorithm for calculating N-sulfatase mutants with enhanced thermal stability
[0055] The crystal structure of the glycosylated wild-type N-sulfotransferase (L557-R882 part of NCBI accession number P52848.1, NST) protein and the crystal structure of the wild-type N-sulfotransferase protein lacking glycosylation were input into the simulation software gromacs, and a 20 ns kinetic simulation was performed at 298 K under default conditions. The amino acid RMSF values were extracted, and the change in RMSF values with and without glycosylation was calculated as ΔRMSF. The results are shown in Figure 1 As shown, then The more concentrated amino acid site regions serve as the focus of subsequent mutation studies.
[0056] The homologous sequences of wild-type N-sulfotransferase from Homo sapiens (L557-R882 part of NCBI accession number P52848.1, NST) were retrieved by NCBI homology search. More than 1000 homologous sequences were manually selected. After homologous sequence alignment using Jalview software, the gap region was manually deleted and the conservation of each amino acid residue was calculated (with 10 as the maximum value). The results are shown in the figure. Figure 2The higher the value, the more conservative the site is. The amino acid site region with a score <8 is used as the focus of subsequent mutation research.
[0057] According to the above kinetic simulation and homologous sequence information ( Figure 1 and Figure 2 ), select and 39 amino acid residues with conservation scores <8, namely: G625, S637, E660, T669, D682, V685, R688, A691, K698, V699, T701, N705, D721, S738, S741, S742, K743, I761, A767, Y768, H769, A770, N771, Q772, K779, E784, K787, M791, T801, H805, T807, G823, E839, L842, D843, A846, Y864, T869, and T872.
[0058] The inventors used the PROSS algorithm to calculate and design four N-sulfatase (NST) mutants that are beneficial to enhancing stability within the above 39 sites, namely:
[0059] NST-design1: G625S, S637P, S741P, A767Y, E839P, T869P, 6 amino acids mutated compared to the wild-type N-sulfotransferase;
[0060] NST-design2: G625S, S637P, V699I, D721N, S738D, T807H, L842E, S741P, A767Y, E839P, T869P, 11 amino acids mutated compared to the wild-type N-sulfotransferase;
[0061] NST-design3: G625S, S637P, E660D, V699I, D721N, S738D, K743E, K779Q, E784D, T807H, L842E, S741P, A767Y, E839P, T869P, 15 amino acids mutated compared to the wild-type N-sulfotransferase;
[0062] NST-design4: G625S, Y634F, S637P, H649N, E660D, V699I, D721N, T729S, S738D, S742K, K743E, A746D, K779Q, M791E, H805S, E784D, T807H, L842E, S741P, A767Y, E839P, T869P, 22 amino acids mutated compared to the wild-type N-sulfotransferase.
[0063] Then the N-sulfatase mutant NST-design1-4 was expressed and purified as a recombinant protein, and the activity and stability of the purified protein were tested. The test results are as follows: Figure 3 shown.
[0064] Depend on Figure 3 It can be seen that among the N-sulfatase mutants NST-design1-4, NST-design3 with 15 mutations showed the best activity and stability as well as the highest expression. We named it NST-M1, the first generation mutant. Among them, the 39 hotspot amino acid sites obtained by PROSS algorithm analysis successfully iterated 15 mutations in NST-M1, leaving 24 hotspot amino acid sites.
[0065] Example 2. Virtual saturation mutation and single point mutation activity determination of N-sulfatase mutant M1
[0066] The NST-M1 mutant modeled by homology modeling using SWISS-MODEL was input into the molecular simulation software Discovery Studio. The remaining 24 sites were mutated into another 19 amino acids using the virtual mutation function of the software. The change in folding free energy ΔΔG after mutation was used as the main reference. The stability after mutation was evaluated using the ΔΔG value. Values greater than 0 were predicted to be mutations that were not conducive to protein stability, and values less than 0 were speculated to be mutations that might be conducive to protein stability. In addition, several obviously unfavorable amino acid mutations were manually deleted. The results are shown in Figure 2. Figure 4 As shown in the figure, the boxed position is the designed site mutation.
[0067] Depend on Figure 4 It can be seen that 9 invalid sites were deleted from the remaining 24 sites, and the remaining 15 sites had single point mutations.
[0068] Then follow Figure 4 The predicted NST mutations were used to express and purify the N-sulfatase mutant recombinant protein, and the activity and stability of the purified protein were measured. The wild-type N-sulfatase was used as a control. The results were as follows Figure 5shown.
[0069] Depend on Figure 5 It can be seen that the NST mutations predicted in this example hit the following 17 stability-enhancing points: T872L, T801I, T701I, S742K, S742R, D843E, A846K, I761L, K787D, M791I, Y864K, Y864H, R688K, K698V, Y768Q, Y768N and N771S.
[0070] Example 3. Iterative evolution of N-sulfatase mutants
[0071] The 17 single-point mutants with significantly improved stability obtained in Example 2 were divided into four groups according to their spatial position relationship:
[0072] Group 1: T872L, T801I and T701I;
[0073] Group 2: S742K, S742R, D843E, and A846K;
[0074] Group 3: I761L, K787D, M791I, Y864K, and Y864H;
[0075] Group 4: R688K, K698V, Y768Q, Y768N and N771S.
[0076] Then, NST-M1 was used as the parent, and NST mutations were set in each group with two mutations or three superimposed combined mutants. Then, the N-sulfotransferase mutant recombinant protein was expressed and purified according to this mutation to obtain the N-sulfotransferase mutant. The activity and stability of the purified protein were then measured, and NST-M1 (design 3) was used as a control. The results are shown in Figure 2. Figure 6 As shown. Figure 6 The optimal mutants in each group can be obtained.
[0077] Subsequently, the optimal T872L / T801I double mutant (NST-M2) of group 1 iteration was combined with the optimal S742K / D843E / A846K triple mutant (NST-M3) of group 2 iteration to form a five-mutant (NST-M6) of T872L / T801I / S742K / D843E / A846K. The optimal I761L / Y864H double mutant (NST-M4) of group 3 iteration was combined with the optimal R688K / N771S double mutant (NST-M5) of group 4 iteration to form a four-mutant (NST-M7) of I761L / Y864H / R688K / N771S. Finally, the five mutants of T872L / T801I / S742K / D843E / A846K (NST-M6) and the four mutants of I761L / Y864H / R688K / N771S (NST-M7) were combined to obtain the nine mutants of T872L / T801I / S742K / D843E / A846K / I761L / Y864H / R688K / N771S (NST-M8) with the highest activity and stability. The mutant NST-M8 had mutations at 9 sites relative to the mutant NST-M1, and at 24 sites compared to the wild-type N-sulfotransferase.
[0078] Then, the recombinant protein of NST-M8 was expressed and purified, and the activity and stability of the purified protein were tested. The wild-type N-sulfotransferase and NST-M1 were used as controls. The test results are shown in Figure 7 shown.
[0079] Depend on Figure 7 It can be seen that compared with the wild-type N-sulfotransferase, the activity of NST-M8 is increased by 2.5 times and the stability is increased by 11.3 times, indicating that the N-sulfotransferase mutant M8 can effectively improve the efficiency of the chemoenzymatic synthesis of heparin and expand the application range of N-sulfotransferase.
[0080] Example 4: Determination of the temporal stability of the 8th generation mutant of N-sulfatase (NST-M8)
[0081] The purified wild-type N-sulfotransferase and NST-M8 protein were incubated at 37°C for 0, 1, 2, 3, 4, 5, 6, 7, 8, and 9 days, and their residual enzyme activities were measured. Figure 8 shown.
[0082] Depend on Figure 8It can be seen that the wild-type N-sulfotransferase basically lost all its activity after being incubated at 37°C for 1 day, while NST-M8 still maintained more than 50% of its activity after being incubated at 37°C for 7 days. This shows that the N-sulfotransferase mutant M8 has extremely high stability compared to the wild-type N-sulfotransferase, indicating that it has extremely high application value and potential in heparin synthesis, making it possible to synthesize heparin at high temperatures, greatly promoting the development of heparin biomimetic synthesis and application.
Claims
1. A N-sulfatase mutant M8, It is characterized in that Its amino acid sequence is shown in SEQ ID NO.
2. The N-sulfotransferase mutant M8 is a wild-type N-sulfotransferase in which 24 amino acids are mutated; the mutations are specifically: G625S, S637P, E660D, R688K, V699I, D721N, S738D, S742K, K743E, I761L, N771S, K779Q, E784D, T801I, T807H, L842E, D843E, S741P, A767Y, E839P, A846K, T869P, Y864H, and T872L.
2. A gene encoding the N-sulfatase mutant M8 according to claim 1.
3. The coding gene according to claim 2, It is characterized in that It is characterized in that The nucleotide sequence is shown as SEQ ID No.
2.
4. The N-sulfotransferase mutant M8 according to claim 1, It is characterized in that The wild-type N-sulfotransferase is the N-Sulfotransferase domain (L557-R882) of the wild-type human N-deacetyl / N-sulfotransferase NDST-1, and the N-Sulfotransferase domain contains 325 amino acids; the NCBI accession number of the wild-type human N-deacetyl / N-sulfotransferase NDST-1 is P52848.
1.
5. A recombinant vector containing a gene encoding the N-sulfatase mutant M8 according to claim 3.
6. A recombinant host cell containing a gene encoding the N-sulfatase mutant M8 according to claim 3.
7. A method for producing the N-sulfatase mutant M8 according to claim 1 by fermentation, It is characterized in that The method comprises culturing the host cell according to claim 6 and isolating and obtaining the N-sulfatase mutant according to claim 1.
8. The method according to claim 7, It is characterized in that The recombinant host cells containing the coding gene of the N-sulfatase mutant M8 according to claim 3 are cultured in LB liquid culture medium until OD600 is 0.6-0.8, and IPTG is added to induce expression for 16-18 hours; the bacteria are collected, ultrasonically disrupted, centrifuged and filtered, and purified through the GST tag to obtain the N-sulfatase mutant M8.
9. Use of the N-sulfatase mutant M8 according to claim 1 in the synthesis of N-site sulfated heparin oligosaccharides and polysaccharides.
10. The use according to claim 9, It is characterized in that The application is to use 3'-phosphoadenosine-5'phosphosulfate (PAPS) as a donor to obtain -GlcNH 2 Heparin oligosaccharides and polysaccharides with -GlcA- structure act as starting acceptors and catalyze the reaction to generate N-sulfated oligosaccharides and polysaccharides with the structure of -GlcNS-GlcA-.
Citation Information
Patent Citations
Expression method for heparin precursor sulphation modification enzyme
CN106754808A
High throughput assay for N-sulfotransferase activity of glucosaminyl N-deacetylase / N-sulfotransferases
US20030109501A1
